Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double blind placebo controlled parallel group comparison of atomoxetine (Strattera) for generalized social anxiety disorder.

Next Previous
Trial Profile

Double blind placebo controlled parallel group comparison of atomoxetine (Strattera) for generalized social anxiety disorder.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 14 Dec 2008 Primary endpoint changed from Liebowitz Social Anxiety Scale to Clinical Global Impressions Scale as reported by ClinicalTrials.gov.
  • 15 Sep 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
  • 15 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top